Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Data from an early-stage study shows that treatment with Ionis' (IONS) ION582 helps improve communication, cognition and motor function in patients with Angelman syndrome, a rare nerve disorder.
Ionis Pharmaceuticals stock surged Monday after the company unveiled promising results for a drug that treats a rare genetic condition.